Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low – Time to Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) hit a new 52-week low on Thursday . The company traded as low as $784.32 and last traded at $784.95, with a volume of 612102 shares. The stock had previously closed at $804.33.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on REGN. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 target price on the stock. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Price Performance

The company has a fifty day simple moving average of $985.21 and a 200 day simple moving average of $1,032.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quent Capital LLC increased its position in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in Regeneron Pharmaceuticals by 26.8% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 124 shares in the last quarter. Acadian Asset Management LLC increased its position in Regeneron Pharmaceuticals by 37.2% in the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after buying an additional 16,856 shares in the last quarter. Cercano Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $36,953,000. Finally, Edgestream Partners L.P. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $7,352,000. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.